Valuation: HilleVax, Inc.

Capitalization 87.79M 84.85M 80.1M 70.67M 126M 7.62B 139M 954M 354M 3.16B 329M 322M 13.37B P/E ratio 2024 *
-0.69x
P/E ratio 2025 * -0.95x
Enterprise value -126M -122M -115M -102M -181M -10.95B -200M -1.37B -509M -4.55B -473M -464M -19.22B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
80.7%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.02%
1 week-7.59%
Current month-10.41%
1 month-11.75%
3 months-10.41%
6 months+11.01%
Current year-14.73%
More quotes
1 week
1.76
Extreme 1.76
1.97
1 month
1.76
Extreme 1.76
2.04
Current year
1.76
Extreme 1.76
2.15
1 year
1.55
Extreme 1.55
20.22
3 years
1.55
Extreme 1.55
24.42
5 years
1.55
Extreme 1.55
24.42
10 years
1.55
Extreme 1.55
24.42
More quotes
Director TitleAgeSince
Chief Executive Officer 62 2020-03-24
Director of Finance/CFO 43 2023-01-05
Chief Tech/Sci/R&D Officer - 2021-12-31
Manager TitleAgeSince
Chairman 62 2020-03-24
Director/Board Member 37 2021-01-31
Director/Board Member 55 2021-07-31
More insiders
Name Weight AuM 1st Jan change Investor Rating
0% 9 M€ +3.40% -
More ETFs: HilleVax, Inc.
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-3.02%-7.59%-88.61% - 87.79M
+0.59%+0.46%+36.26%-0.85% 48.01B
-2.92%+0.76%-7.49%-17.48% 36.45B
+0.39%+2.10%+5.06%+22.26% 26.18B
-1.19%-2.69%-32.36%-28.10% 15.76B
+2.55%+0.25%+63.85%+74.05% 15.43B
-2.98%-9.47%-65.24%-80.82% 12.26B
-2.62%-6.11%-2.62%-34.90% 11.05B
-6.92%-5.07%+1.59%+88.32% 10.99B
+3.51%+13.19% - - 10.76B
Average -1.29%-0.35%-9.95%+2.81% 18.7B
Weighted average by Cap. -0.76%+0.74%+7.13%+1.13%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -130M -126M -119M -105M -186M -11.28B -206M -1.41B -524M -4.69B -487M -477M -19.79B -97.89M -94.61M -89.32M -78.8M -140M -8.49B -155M -1.06B -395M -3.53B -367M -360M -14.9B
Net Debt -214M -207M -195M -172M -306M -18.57B -340M -2.32B -863M -7.71B -802M -786M -32.58B -
More financial data * Estimated data
Logo HilleVax, Inc.
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Employees
90
More about the company
Date Price Change Volume
25-02-11 1.765 $ -3.02% 279,548
25-02-10 1.820 $ -2.15% 266,786
25-02-07 1.860 $ -3.12% 217,747
25-02-06 1.920 $ -2.04% 160,629
25-02-05 1.960 $ +2.62% 122,334

Delayed Quote Nasdaq, February 11, 2025 at 01:47 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.820USD
Average target price
3.000USD
Spread / Average Target
+64.84%
Consensus

Quarterly revenue - Rate of surprise